US FDA expands indications for brivaracetam and eslicarbazepine

560 Views

eMediNexus 19 September 2017

The US FDA has expanded the indications for two anti-epileptic drugs, brivaracetam and eslicarbazepine. Brivaracetam is now approved as monotherapy for partial-onset seizures in epilepsy patients aged 16 years and older. Eslicarbazepine is now approved to treat partial-onset seizures in children and adolescents aged 4 to 17 years.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.